Characterisation of Fibrinogen Oslo IV by Electrospray Mass Spectrometry

Thromb Haemost 1997; 77(05): 1040-1041
DOI: 10.1055/s-0038-1656104

Letter to the Editor

Schattauer GmbH Stuttgart

S O Brennan

¹Molecular Pathology Laboratory, Canterbury Health Laboratories, Christchurch Hospital, Christchurch, New Zealand

,

H Ridgway

¹Molecular Pathology Laboratory, Canterbury Health Laboratories, Christchurch Hospital, Christchurch, New Zealand

,

H Stormorken

²Nycomed Pharma AS, Gausladalléen 21, N-0371, Oslo, Norway

,

F Brosstad

³Institute for Research in Internal Medicine, Rikshospitalet, Oslo, Norway

,

P M George

¹Molecular Pathology Laboratory, Canterbury Health Laboratories, Christchurch Hospital, Christchurch, New Zealand

References
1 Stormorken H, Brosstad F, Seim H. A new dysfibrinogenemia: Fibrinogen Oslo IV. Thromb Haemost 1983; 49: 120-122
2 Brennan SO, Hammonds B, George PM. Aberrant hepatic processing causes removal of activation peptide and primary polymerisation stie from fibrinogen Canterbury (Aα 20→Val Asp). J Clin Invest 1995; 96: 2854-2858
3 Blombäck B, Hessel B, Fields R, Procyk R. Fibrinogen Aarhus: An abnormal fibrinogen with Aα19 Arg→Gly substitution. In: Fibrinogen 3: Biochemical and Biological Function, Gene Regulation and Expression. Mosesson MW, Amrani DL, Siebenlist KR, Di Orio JP. eds. Elsevier Scientific Publishers BV. 1988: 263-266
4 Dempfle C-EH, Henschen A. Fibrinogen Mannheim I: Identification of an Aα19→ArgGly substitution in dysfibrinogenaemia associated with bleeding tendency. In: Fibrinogen 4: Current Issues and Clinical Aspects. Matsuda M, Iwanga S, Takada A, Henschen A. eds. Elsevier Scientific Publishers BV. 1990: 159-165
5 Yamaguchi FI, Sugo T, Hashimoto Y, Kimura K, Okajima K, Matsuda M. Fibriogen Kumamoto with an A α 19→Gly substitution associated clinically with thrombosis. Fibrinolysis 1996; 10 (Suppl. 04) 23